HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria

Exclusion Criteria

• •1. Type I diabetes
• •2. Uncontrolled diabetic patients with HbA1c \> 10% at screening
• •3. Hypertensive patients whose mean blood pressure was not controlled at 160/90 mmHg or more in triplicate despite the use of antihypertensive agents at the time of randomization
• •4. Calculated LDL-C ≥ 160 mg/dL at randomization
• •5. Patients who have taken RAS blockers (ACE inhibitor, ARB, and Aldosterone antagonist) for 4 weeks prior to randomization
• •6. Heart failure patients with NYHA class IV
• •7. Patients with acute and chronic liver disease, acute inflammation, hematologic abnormalities and cancer within the last 6 months
• •8. Patients with a history of cerebral blood cardiovascular complications (cerebral infarction, transient ischemic attack, myocardial infarction, unstable angina, coronary artery bypass, and percutaneous coronary intervention)
• •9. Patients taking immunosuppressive drugs
• •10. Patients undergoing eGFR \<30 mL/min/1.73 m2 (CKD-EPI formula) or renal replacement therapy (dialysis or renal transplant) at screening
• •11. Patients with a change in eGFR (CKD-EPI formula) value showing a difference of more than 30% in the last 6 months at screening
• •12. Creatine kinase (CK) level ≥ 3x ULN (upper limit of normal range)
• •13. Patients who are pregnant or planning to become pregnant
• •14. Contraindications stated in the SPC of telmisartan or rosuvastatin
• •15. Those participating in other clinical trials for investigational products at screening
• •16. Patients deemed to be ineligible to participate in the trial by investigator